$19.22 Million in Sales Expected for Clovis Oncology, Inc. (CLVS) This Quarter
Equities analysts expect Clovis Oncology, Inc. (NASDAQ:CLVS) to post $19.22 million in sales for the current quarter, Zacks reports. Five analysts have made estimates for Clovis Oncology’s earnings. The highest sales estimate is $20.00 million and the lowest is $18.61 million. Clovis Oncology reported sales of $80,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 23,925%. The firm is expected to report its next earnings report on Wednesday, February 28th.
On average, analysts expect that Clovis Oncology will report full-year sales of $19.22 million for the current financial year, with estimates ranging from $55.27 million to $58.47 million. For the next year, analysts anticipate that the company will post sales of $209.03 million per share, with estimates ranging from $168.20 million to $279.59 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Clovis Oncology.
Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($1.18) by ($0.06). Clovis Oncology had a negative net margin of 947.47% and a negative return on equity of 122.06%. The firm had revenue of $16.81 million for the quarter, compared to analyst estimates of $21.12 million. During the same quarter in the prior year, the firm earned ($1.70) earnings per share.
Clovis Oncology (NASDAQ:CLVS) opened at $55.87 on Friday. Clovis Oncology has a 1 year low of $45.42 and a 1 year high of $99.45. The company has a market cap of $2,692.39, a P/E ratio of -6.75 and a beta of 1.39. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.16 and a current ratio of 3.19.
In related news, Director Thorlef Spickschen sold 4,500 shares of the business’s stock in a transaction on Monday, January 8th. The shares were sold at an average price of $64.97, for a total value of $292,365.00. Following the sale, the director now owns 21,118 shares of the company’s stock, valued at $1,372,036.46. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $63.70, for a total transaction of $191,100.00. The disclosure for this sale can be found here. In the last three months, insiders sold 18,000 shares of company stock worth $1,123,425. 12.50% of the stock is currently owned by insiders.
Institutional investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company grew its stake in shares of Clovis Oncology by 18.3% in the second quarter. The Manufacturers Life Insurance Company now owns 30,408 shares of the biopharmaceutical company’s stock worth $2,847,000 after purchasing an additional 4,699 shares during the last quarter. Gabelli Funds LLC boosted its position in Clovis Oncology by 75.0% during the third quarter. Gabelli Funds LLC now owns 15,400 shares of the biopharmaceutical company’s stock valued at $1,269,000 after acquiring an additional 6,600 shares during the last quarter. Columbus Circle Investors boosted its position in Clovis Oncology by 74.4% during the third quarter. Columbus Circle Investors now owns 213,674 shares of the biopharmaceutical company’s stock valued at $17,607,000 after acquiring an additional 91,142 shares during the last quarter. Prudential Financial Inc. boosted its position in Clovis Oncology by 1,416.9% during the third quarter. Prudential Financial Inc. now owns 66,560 shares of the biopharmaceutical company’s stock valued at $5,485,000 after acquiring an additional 62,172 shares during the last quarter. Finally, BB&T Securities LLC bought a new stake in Clovis Oncology during the third quarter valued at $288,000.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.